Treatment for cancer continues to drive immense innovation in the drug development pipeline, with advanced cell therapies, vaccines, and ADCs taking center stage.
Alicia Bigica
Advertisement
Articles by Alicia Bigica
Contract development and manufacturing organizations (CDMOs) are more critical than ever as the demand for advanced therapies continues to grow.
As the industry adjusts to new regulations, including Annex 1, bio/pharma manufacturers must rethink facility designs to remain in compliance.
BioPharm International sat down with Christa Myers of CRB Group and Nadiyra Walker Speight of Fujifilm Diosynth Biotechnologies at INTERPHEX 2024 to examine the implementation of Annex 1.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Trends in Formulation eBook October 2025
2
In KPMG's CEO Outlook, AI, Regulatory Demands, and Supply Chain Risk Rank High
3
New Cellevate Nanofiber Microcarriers Aim to Transform Vaccine Manufacturing Processes
4
Analytics, Automation, and Quality Driving the Next Era of Drug Development
5
